Dr. Karan Sood

Do participate in this Global survey initiated by Dr Karan Sood @QuantumOnc and colleagues Asthenia isn't rare It is ignored. Let's understand it better @MedwatchKate @Larvol @OncBrothers @allisonoconn @PTarantinoMD @dr_yakupergun Link below 🙂👇 docs.google.com/forms/d/e/1FAI… .

📊Early insights on Asthenia Survey: 89.4% see it often 68.2% aren’t satisfied with the current treatment "Asthenia is common." Our systems to address it? Not enough. ⏱4 minutes to contribute 🔁Please reshare to expand reach 🔗 forms.gle/R6oz4zWioxrjAS…

2026 is the year capital flows into biotech. 2012 - CRISPR discovered, nobody knows what to do with it 2018 - Gene therapy costs $2M per treatment, completely unscalable 2020 - mRNA works but gets written off as a COVID fluke 2023 - AI eats software, biotech still stuck in 20-year timelines 2024 - Autonomous labs emerge, longevity gets institutional backing 2025 - FDA shifts, manufacturing costs drop 40%, DeSci bypasses gatekeepers 2026 - AI running 36K experiments autonomously, gene therapy costs dropped 40%, FDA fast-tracking, €2.5M crowdfunded in 72 hours, and biology just hit software velocity bio/acc.

🔥🚨BREAKING: A petri dish filled with human brain cells just learned to how to play DOOM Scientists at Cortical Labs have successfully trained a cluster of approximately 200,000 living human neurons, grown on a microelectrode array chip, to play the classic 3D video game DOOM.

@QuantumOnc @AnantRamaswamy @nihanthy @SuyogCancer @darioT_ @pankajpanda86 @ClinoncPushpen @pokhrel_bidushi Please follow the link and help gather data on asthenia in cancer care. It is helpful to have better insight in the subject.

📊 Initial survey results show asthenia is encountered >60% in metastatic cancer patients, yet most oncologists are “Not satisfied” with the current management. Take this 4-minute survey & help us understand this: forms.gle/R6oz4zWioxrjAS… #Asthenia #CancerCare #qualityoflife

@AnantRamaswamy @nihanthy @SuyogCancer @darioT_ @pankajpanda86 @ClinoncPushpen @pokhrel_bidushi @PTarantinoMD @JCOGO_ASCO @purvish1 @ajumathew_ @maryam_lustberg @TataMemorialCtr @TataMemorial @nihardesai89 @NazliDizman @SewantiLimaye @BalazsHalmosMD @EHA_Hematology @Amolpatel_dr @oncology_bg

Tomás Vega invented a MouthPad, a groundbreaking device that enables people with paralysis to control digital devices using tongue, mouth, and head gestures.

A brief history of p53-targeting cancer therapies 2003 — Gendicine, a p53 gene therapy, approved in China (but not elsewhere) 2012 — The first small molecule MDM2 inhibitor (RG7112, which works by preventing degradation of p53) enters trials, but did not progress to approval 2013 — Second-generation MDM2 inhibitor (Idasanutlin) reached phase 3, but failed and was dropped 2017 — A dual MDM2/MDMX inhibitor, ALRN-6924, enters trials; it has not since been approved 2020–2021 — A mutant p53 reactivator, Eprenetapopt, fails in phase 3 2023 — An MDM2 inhibitor, Milademetan, fails in phase 3 2024 — Promising phase 1 data for an MDM2 degrader 2026 — Rezatapopt phase 1 data: very promising early data, specific for the p53 Y220C mutation (present in 1% of all solid tumours)

Our cancer support session on Managing the Side Effects of Treatment During Cancer Treatment brought together expert medical guidance and meaningful patient conversations. With insights from Dr. Karan Sood, Medical Oncologist, the discussion focused on understanding common treatment-related side effects, practical management strategies, and improving day-to-day quality of life during cancer care. The session featured patient perspective from Ms. Urvashi Prasad and was hosted by Mr. Vivek Sharma, Founder of Uhapo, reinforcing a shared commitment to patient support and empowerment. Thank you to everyone who joined and contributed to making this session informative and impactful. Watch on YouTube - youtu.be/Bk2g1nfSDhU?si… #CancerSupport #OncologyCare #PatientWellbeing #Uhapo #CancerCommunity

☘️This week is "World CCA Week" (16-22 February) 🟢Recognize cholangiocarcinoma! #GreenForCCA #IluminaEnVerde26 @PrecisionBTCnet @CCA_Alliance @curecc @OncoAlert

Glad to share that our faculty and researchers published 36 papers in high-impact journals, including six in @TheLancetOncol @JCO_ASCO @BloodPortfolio @Annals_Oncology, in Jan 2026, advancing science and shaping cancer care in India and globally! @ACTREC_TMC @TataMemorial

This is it

@Erman_Akkus @AnantRamaswamy @SuyogCancer @Amolpatel_dr @VanitaNoronha @sajconline @IJMPOofficial @VirajLavingia @ChandrakanthMv For LDIO, excluding the signet ring and her2+ cohort might have given a tough fight to SDIO. Moreover genomic characterization might point to the molecular subset that we should select to get the max benefit from LDIO. Amazing study @AnantRamaswamy sir!

@AnantRamaswamy @SuyogCancer @Amolpatel_dr @VanitaNoronha @sajconline @IJMPOofficial @VirajLavingia @ChandrakanthMv @QuantumOnc As an speculation, CPS would be a matter with low dose ICI. Would be good to check EBV if possible.

Data on Low dose ICIs in MSS gastric cancers - propensity matched data - Thoughts and views ? sciencedirect.com/science/articl… @SuyogCancer @Amolpatel_dr @VanitaNoronha @sajconline @IJMPOofficial @VirajLavingia @ChandrakanthMv @Erman_Akkus @QuantumOnc

Nuanced and balanced discussion on MRD directed therapy in myeloma. Excellent write up by @MirghSumeet . Followed an excellent presentation by @QuantumOnc and JC discussion by the myeloma geeks on #MIDAS in @lingarajnayak @PrashantTembha1 @P_G_Subramanian @nvpatkar @RajpalSweta

What if we’ve been overdosing immunotherapy all along? In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! ascopubs.org/doi/10.1200/JC… @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer

🔥(1/7) Finally out after a very long journey, the main results from the BioItaLEE trial: a prospective study primarily aimed to evaluate ctDNA dynamics during 1st line ribo/let. A huge team effort with many Italian colleagues and friends 🇮🇹 👇👇 thread🧵 aacrjournals.org/clincancerres/…

This is the future

FDA grants Breakthrough Therapy Designation to @EliLillyandCo Sofetabart Mipitecan (LY4170156) in platinum-resistant ovarian cancer. This isn’t just "another ADC." This is the paradigm shift we’ve been waiting for👇🏻 1. The "Post-Elahere" Solution: Unlike current SOC, Sofetabart shows robust activity in patients refractory to prior mirvetuximab (Elahere). Why? It swaps the tubulin-inhibitor payload (DM4) for a Topoisomerase-I inhibitor (exatecan). No cross-resistance = new runway for our patients. 2. The "Low-Expressor" Unlock: Current approval is limited to FRα-High (≥75%). Sofetabart showed responses across ALL expression levels (High, Moderate, & Low). Impact: We move from treating ~35% of PROC patients to potentially >80%. 3. The Clinician’s Win (Safety): 🚩 NO significant ocular toxicity reported. No keratopathy. No mandatory eye exams. Low rates of neuropathy/alopecia. This is a massive QoL win compared to current ADC burdens. The Bottom Line:🧠 Phase 3 FRAmework-01 is now the trial to watch. If these signals hold, we are looking at the new backbone for PROC-replacing chemo in the FRα-Low setting and rescuing the FRα-Highs post-progression. @ocrahope @Ovacome #gyncsm #ovariancancer #oncology #drugdevelopment #ASCO25 @OncoAlert investor.lilly.com/news-releases/…